Michael J. Mauro, MD, on the ENABLE Study in Heavily Pretreated Patients With CML

September 15, 2025 By The ASCO Post Staff

Michael J. Mauro, MD, of Memorial Sloan Kettering Cancer Center, reviews findings from the phase Ia/Ib ENABLE study, which evaluated ELVN-001, a highly selective, active-site inhibitor designed to target BCR-ABL1, in heavily pretreated patients with chronic myeloid leukemia (CML). 

Related Content